今年以来“翻倍基”数量达16只

Group 1 - The equity market has shown significant profit effects this year, with equity assets becoming a major driver for the net value growth of public funds. As of August 15, the number of funds with a net value growth rate exceeding 100% has reached 16 [1] - Among these "doubling funds," 15 have heavily invested in the innovative drug sector, benefiting from the ongoing performance of this market segment. The future performance of the innovative drug sector is expected to remain promising due to still relatively low valuations of some targets [1][2] - As of August 15, there are a total of 209 funds with a net value growth rate of over 50% this year, with 16 of them achieving over 100% growth [1] Group 2 - The top-performing fund, Huatai-PB Hong Kong Advantage Selected Mixed (QDII) A, has a year-to-date net value growth rate of 143.24%. The fund continues to favor the innovative drug direction with a stock investment ratio of 92.65% as of the end of Q2 [2] - Other funds, such as Changcheng Medical Industry Selected Mixed and Bank of China Hong Kong Stock Connect Medical Mixed, also focus on the innovative drug theme. The fund manager of Nuon Selected Value Mixed noted that the innovative drug sector has been driven by expectations of large external licensing deals [2] - The impressive performance has attracted continuous market inflows, leading to significant growth in the scale of some "doubling funds." As of August 14, the listed fund scales of GF CSI Hong Kong Innovative Drug (QDII-ETF) and Huatai-PB National Index Hong Kong Stock Connect Innovative Drug ETF have reached 19.043 billion and 14.994 billion respectively [2] Group 3 - The fund manager of Huatai-PB Hong Kong Advantage Selected Mixed (QDII) believes that the market's investment understanding of the innovative drug sector is still evolving, with continuous emergence of unexpected overseas projects driving overall valuation increases [3] - The innovative drug sector is currently in a historical phase where domestic innovative drugs are transitioning from imitation to following and then to surpassing. The potential upper limit of this innovative drug market cycle is expected to exceed the previous cycle where domestic pharmaceutical companies acted as outsourcing partners for overseas firms [3] - Despite the high year-to-date growth of the innovative drug sector, the valuation of the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index is at a historically low level, indicating significant upside potential. The core driving logic of innovative drugs—domestic policy benefits and globalization breakthroughs—remains unchanged in the long term [3]